Volume 5, Issue 4 (2024) – 11 articles
Cover Picture: With properties like efficient cellular uptake, low immunogenicity, and stable performances, celery-derived extracellular vesicles (CDEVs) show potential as a new type of anti-tumor nanomedicine. In vitro experiments, including co-culture, Western blot, and flow cytometry, demonstrated that CDEVs effectively attenuated the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3) and downregulated programmed cell death ligand 1 (PD-L1) expression in lung cancer cells. This disruption of the PD-L1/programmed death 1 (PD-1) axis alleviated T cell suppression, enhancing immune activation. In vivo studies using C57BL/6 mice subcutaneously implanted with Lewis lung carcinoma (LLC) cells revealed that CDEVs loaded with paclitaxel (PTX) exhibited superior tumor-targeting efficiency. Treatment with CDEVs-PTX notably elevated CD8+ T cell levels, correlating with enhanced anti-tumor immune responses. These findings highlight CDEVs as dual-function agents, serving both as drug carriers and active therapeutics, enabling the integration of immunotherapy and chemotherapy in a single administration. This dual-modal approach offers a comprehensive cancer treatment strategy, potentially improving therapeutic outcomes while reducing treatment-related adverse effects.
view this paper 
